Arian Lundberg

I am a medical and translational cancer bioinformatician specialized in inflammation-driven tumor evolution, immune–metabolic rewiring, and lineage plasticity in metastatic prostate cancer, breast cancer and Head and Neck cancers.
My work integratesmulti-omics,machine learning, andAI-driven mechanistic modeling to uncover how inflammatory and microenvironmental signals drive progression and therapy resistance. The overarching goal is to identifyactionable biomarkers, predictive models, and targetable vulnerabilities in lethal disease.

I completed my PhD at Karolinska Institute, focusing on transcriptomic biomarkers for therapy stratification in breast cancer. My postdoctoral training at Stanford University, University of California San Francisco, and the Institute of Cancer Research / Royal Marsden Hospital centered on immune-responsive cancers and translational prostate cancer genomics, including major contributions to the SU2C WCDT, the most comprehensive multi-omics cohort of metastatic prostate cancer in the U.S.

In 2024, I was awarded the Knut and Alice Wallenberg Data-Driven Life Science Fellowship in Precision Medicine and Diagnostics to launch my independent research program at KTH Royal Institute of Technology.

A. Lundberg Lab's Mission

We uncover how inflammation and immune–metabolic signals reshape tumor evolution in metastatic prostate cancer, using multi-omics and advanced AI/ML models grounded in clinical data.

1. Inflammation-driven plasticity in metastatic prostate cancer
Dissecting transcriptional, metabolic, and regulatory programs that enable therapy escape.

2. AI- and ML-powered multi-omics biomarkers
Developing robust predictive models for survival, treatment response, mitochondrial activity, immune infiltration, and tumor phenotypes.

3. Immune–metabolic and microenvironmental rewiring
Using deep learning and integrative omics to map how inflammatory and metabolic cues reshape cell state trajectories.

4. Microbiome–tumor–immune crosstalk
Identifying microbial drivers and inflammatory mediators linked to progression and resistance.

Vision

To build the first AI-driven, mechanistically grounded framework for predicting and targeting inflammation-fueled tumor evolution in advanced prostate cancer.